Drug Information
Drug (ID: DG00324) and It's Reported Resistant Information
Name |
Bendamustine hydrochloride
|
||||
---|---|---|---|---|---|
Synonyms |
Treanda (TN)
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(2 diseases)
Chronic lymphocytic leukemia [ICD-11: 2A82]
[1]
Mature B-cell neoplasms/lymphoma [ICD-11: 2A85]
[2]
|
||||
Target | Human Deoxyribonucleic acid (hDNA) | NOUNIPROTAC | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C16H21Cl2N3O2
|
||||
IsoSMILES |
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
|
||||
InChI |
1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)
|
||||
InChIKey |
YTKUWDBFDASYHO-UHFFFAOYSA-N
|
||||
PubChem CID | |||||
TTD Drug ID | |||||
INTEDE ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Chronic lymphocytic leukemia [ICD-11: 2A82]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Cellular tumor antigen p53 (TP53) | [1] | |||
Molecule Alteration | Mutation | . |
||
Resistant Disease | Chronic lymphocytic leukemia [ICD-11: 2A82.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vivo Model | A retrospective survey in conducting clinical studies | Homo sapiens | ||
Experiment for Molecule Alteration |
Whole exome sequencing assay; Targeted deep sequencing assay; Sanger sequencing assay | |||
Mechanism Description | Following exposure to chemoimmunotherapy, the resistant TP53 aberrant clones accumulate and dominate the tumour. |
Mature B-cell neoplasms/lymphoma [ICD-11: 2A85]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: CXC chemokine receptor type 4 (CXCR4) | [2] | |||
Molecule Alteration | Mutation | . |
||
Resistant Disease | Waldenstrom macroglobulinemia [ICD-11: 2A85.4] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Mechanism Description | CXCR4 mutation led to bendamustine in the waldenstrom macroglobulinemia. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.